Tag: Continuous Glucose Monitoring

NEW YORK - There was a significant connection between having a higher cumulative risk for health inequities and higher engagement with One Drop's educational content, according to new research the company presented at the 82nd Scientific Sessions of the American Diabetes Association. Findings suggest that at-risk individuals with Type 2 diabetes may fill the gaps left by inadequate access to quality health care and systemic discrimination by using digital health solutions. "At One Drop, we have...

When CMS paved the way for coverage of continuous blood glucose monitors (CGMs), it was a shot in the arm for a diabetes market devastated by the competitive bidding program. In the years since, the market has exploded and it shows no signs of slowing down.  In 2020, Medicare spending for CGMs (K0554) was $21,594,764, compared to approximately $4,192,820 in 2017, the year CMS began paying for the devices, according to the HME Databank.   The top provider in 2020: North Coast Medical...

HUDSON, Ohio – GEMCO Medical has entered into a vendor agreement with VGM & Associates to provide the group’s members with wholesale medical supplies, including diabetes testing supplies and continuous glucose monitoring devices, and offer them access to a drop-ship, direct-to-patient program. Also as part of the agreement, VGM will partner with GEMCO Medical’s team of experts to provide webinars and education on the latest products to help members navigate the diabetes...

SAN DIEGO – Dexcom has launched Dexcom Ventures to identify and invest in opportunities to supplement growth in its core business of continuous glucose monitoring and advance the development of adjacent technologies.  Dexcom Ventures, led by Dexcom veteran Steve Pacelli, will be focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening the company’s commitment to advancing better outcomes in health care.  “Driven...

WASHINGTON - CMS seeks to continue paying higher payment amounts to suppliers in non-competitive bidding areas as part of a DMEPOS proposed rule that it published on Tuesday afternoon.The agency also seeks to: permanently exempt manual wheelchairs and accessories from the bid program; classify all continuous glucose monitors, not just therapeutic CGMs, as DME and establish payment amounts for them and their related supplies and accessories; and expand the classification of external infusion pumps...

DUBLIN - Medtronic has expanded its Medtronic Assurance program for U.S. customers who lose their jobs and health insurance due to COVID-19. Current eligible customers can receive a three-month supply of sensors, infusion sets and reservoirs at no cost. “Knowing that concerns around continuity of therapy are at the very top of mind for people living with diabetes, Medtronic wants to ensure during this stressful and challenging time that we can be there for our customers when they need it most,”...

DEERFIELD, Ill. - Walgreens has made a push into the continuous glucose monitoring market, but HME providers warn that providing diabetes care is a different animal than filling prescriptions.The onerous paperwork, alone, would seem to be a huge obstacle for retail pharmacies, says Tim Cady, president of Carlsbad, Calif.-based Advanced Diabetes Supplies, a large distributor of Dexcom products. “The records that are required and the way you need to interpret the local coverage determination...

ABBOTT PARK, Ill. - The FreeStyle Libre System is the second continuous glucose monitoring system approved for Medicare coverage. The Abbott-manufactured system requires no user calibration, reading glucose levels via a sensor worn on the upper arm. Users simply wave a reader over the sensor to get a reading. CMS in early 2017 approved certain CGMs as DME as long as they are approved by the Food and Drug Administration for use in place of a blood glucose monitor for making treatment decisions. The...

WASHINGTON - CMS classified “therapeutic” continuous glucose monitoring systems as durable medical equipment in a Jan. 12 ruling.CMS says CGMs are considered therapeutic and meet the definition of DME if:. They are approved by the FDA for use in place of a blood glucose monitor for making diabetes treatment decisions (for example, changes in diet and insulin dosage);. They are generally not useful to the individual in the absence of an illness or injury;. They are appropriate for use...

SAN DIEGO - Dexcom has received expanded approval from the U.S. Food and Drug Administration for the G5 mobile continuous glucose monitoring system.This is the first FDA-approved continuous glucose monitoring system that can be used to make diabetes treatment decisions without confirmation from a traditional fingerstick test. The system was previously approved to complement, not replace, fingerstick testing for diabetes treatment decisions.“This may allow some patients to manage their disease...